Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Epithelial Ovarian Cancer-Pipeline Review, H1 2015

Epithelial Ovarian Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Epithelial Ovarian Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Epithelial Ovarian Cancer-Pipeline Review, H1 2015', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Epithelial Ovarian Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Epithelial Ovarian Cancer-Overview 11

Pipeline Products for Epithelial Ovarian Cancer-Comparative Analysis 12

Epithelial Ovarian Cancer-Therapeutics under Development by Companies 13

Epithelial Ovarian Cancer-Therapeutics under Investigation by Universities/Institutes 18

Epithelial Ovarian Cancer-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Epithelial Ovarian Cancer-Products under Development by Companies 22

Epithelial Ovarian Cancer-Products under Investigation by Universities/Institutes 27

Epithelial Ovarian Cancer-Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Adaptimmune Limited 29

Amgen Inc. 30

Astex Pharmaceuticals, Inc. 31

AstraZeneca PLC 32

Bayer AG 33

Bionomics Limited 34

BioNumerik Pharmaceuticals, Inc. 35

Boehringer Ingelheim GmbH 36

Celldex Therapeutics, Inc. 37

Celon Pharma Sp. z o.o. 38

Celsion Corporation 39

Cerulean Pharma, Inc. 40

Clovis Oncology, Inc. 41

Eli Lilly and Company 42

Exelixis, Inc. 43

F. Hoffmann-La Roche Ltd. 44

Genentech, Inc. 45

Glycotope GmbH 46

ImmunoGen, Inc. 47

Immunotope, Inc. 48

Johnson & Johnson 49

MabVax Therapeutics Holdings, Inc. 50

Merck & Co., Inc. 51

Millennium Pharmaceuticals, Inc. 52

NeoStem, Inc. 53

Novartis AG 54

Oasmia Pharmaceutical AB 55

OBI Pharma, Inc. 56

Oncobiologics, Inc. 57

Oncolytics Biotech Inc. 58

Onxeo SA 59

Otsuka Holdings Co., Ltd. 60

Oxford BioMedica plc 61

OXiGENE, Inc. 62

Pfizer Inc. 63

Pharma Mar, S.A. 64

Pharmacyclics, Inc. 65

Prima BioMed Ltd. 66

PsiOxus Therapeutics, Ltd. 67

Sanofi 68

Sanofi Pasteur SA 69

Sotio a.s. 70

Synta Pharmaceuticals Corp. 71

Tesaro, Inc. 72

TetraLogic Pharmaceuticals 73

Therapeutic Proteins International, LLC 74

TRACON Pharmaceuticals, Inc. 75

VentiRx Pharmaceuticals, Inc. 76

Epithelial Ovarian Cancer-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Target 78

Assessment by Mechanism of Action 82

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

abexinostat hydrochloride-Drug Profile 89

abiraterone acetate-Drug Profile 92

ABT-898-Drug Profile 95

alisertib-Drug Profile 96

anetumab ravtansine-Drug Profile 100

Antisense Oligonucleotide for Ovarian and Colorectal Cancer-Drug Profile 102

AZD-1775-Drug Profile 103

belinostat-Drug Profile 105

bevacizumab-Drug Profile 108

bevacizumab biosimilar-Drug Profile 113

bevacizumab biosimilar-Drug Profile 114

bevacizumab biosimilar-Drug Profile 115

birinapant-Drug Profile 116

BNC-105P-Drug Profile 119

cabozantinib s-malate-Drug Profile 121

Cancer Stem Cell Therapy-Drug Profile 124

catumaxomab-Drug Profile 125

CDX-1401-Drug Profile 127

Cell Therapy to Target NY-ESO-1 for Oncology-Drug Profile 129

cositecan-Drug Profile 131

CRLX-101-Drug Profile 133

CVac-Drug Profile 135

DCVAC/OvCa-Drug Profile 138

DMUC-4064A-Drug Profile 139

EGEN-001-Drug Profile 140

elesclomol-Drug Profile 142

enadenotucirev-Drug Profile 144

erismodegib-Drug Profile 146

fosbretabulin tromethamine-Drug Profile 149

ganetespib-Drug Profile 153

guadecitabine-Drug Profile 157

IMT-1012-Drug Profile 160

LCL-161-Drug Profile 161

lifastuzumab vedotin-Drug Profile 163

lurbinectedin-Drug Profile 165

LY-2606368-Drug Profile 168

MesoCART-Drug Profile 169

mirvetuximab soravtansine-Drug Profile 170

motolimod-Drug Profile 172

NERX-313E-Drug Profile 174

NERX-505X-Drug Profile 175

nintedanib-Drug Profile 176

niraparib-Drug Profile 181

NSC-748933-Drug Profile 183

OBI-822/821-Drug Profile 184

OPB-111001-Drug Profile 186

paclitaxel-Drug Profile 187

PankoMab-GEX-Drug Profile 189

pelareorep-Drug Profile 190

pembrolizumab-Drug Profile 195

PF-06647263-Drug Profile 202

Procure-Drug Profile 203

Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer-Drug Profile 204

ralimetinib mesylate-Drug Profile 205

regorafenib-Drug Profile 206

rucaparib phosphate-Drug Profile 209

SAR-408701-Drug Profile 212

sorafenib tosylate-Drug Profile 213

trabectedin-Drug Profile 217

TRC-105-Drug Profile 221

trebananib-Drug Profile 224

TroVax-Drug Profile 227

Vaccine for Oncology-Drug Profile 230

Vaccine to Target Carcinoembryonic Antigen for Oncology-Drug Profile 231

Vaccine to Target Cellular Tumor Antigen p53 for Oncology-Drug Profile 232

Vaccine to Target IGFBP-2 for Epithelial Ovarian Cancer-Drug Profile 233

varlilumab-Drug Profile 234

vCP-2292-Drug Profile 236

X-82-Drug Profile 237

Epithelial Ovarian Cancer-Recent Pipeline Updates 239

Epithelial Ovarian Cancer-Dormant Projects 368

Epithelial Ovarian Cancer-Discontinued Products 370

Epithelial Ovarian Cancer-Product Development Milestones 371

Featured News & Press Releases 371

Appendix 376

Methodology 376

Coverage 376

Secondary Research 376

Primary Research 376

Expert Panel Validation 376

Contact Us 376

Disclaimer 377

List of Tables

Number of Products under Development for Epithelial Ovarian Cancer, H1 2015 16

Number of Products under Development for Epithelial Ovarian Cancer-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Epithelial Ovarian Cancer-Pipeline by AbbVie Inc., H1 2015 33

Epithelial Ovarian Cancer-Pipeline by Adaptimmune Limited, H1 2015 34

Epithelial Ovarian Cancer-Pipeline by Amgen Inc., H1 2015 35

Epithelial Ovarian Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 36

Epithelial Ovarian Cancer-Pipeline by AstraZeneca PLC, H1 2015 37

Epithelial Ovarian Cancer-Pipeline by Bayer AG, H1 2015 38

Epithelial Ovarian Cancer-Pipeline by Bionomics Limited, H1 2015 39

Epithelial Ovarian Cancer-Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 40

Epithelial Ovarian Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 41

Epithelial Ovarian Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 42

Epithelial Ovarian Cancer-Pipeline by Celon Pharma Sp. z o.o., H1 2015 43

Epithelial Ovarian Cancer-Pipeline by Celsion Corporation, H1 2015 44

Epithelial Ovarian Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 45

Epithelial Ovarian Cancer-Pipeline by Clovis Oncology, Inc., H1 2015 46

Epithelial Ovarian Cancer-Pipeline by Eli Lilly and Company, H1 2015 47

Epithelial Ovarian Cancer-Pipeline by Exelixis, Inc., H1 2015 48

Epithelial Ovarian Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 49

Epithelial Ovarian Cancer-Pipeline by Genentech, Inc., H1 2015 50

Epithelial Ovarian Cancer-Pipeline by Glycotope GmbH, H1 2015 51

Epithelial Ovarian Cancer-Pipeline by ImmunoGen, Inc., H1 2015 52

Epithelial Ovarian Cancer-Pipeline by Immunotope, Inc., H1 2015 53

Epithelial Ovarian Cancer-Pipeline by Johnson & Johnson, H1 2015 54

Epithelial Ovarian Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 55

Epithelial Ovarian Cancer-Pipeline by Merck & Co., Inc., H1 2015 56

Epithelial Ovarian Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 57

Epithelial Ovarian Cancer-Pipeline by NeoStem, Inc., H1 2015 58

Epithelial Ovarian Cancer-Pipeline by Novartis AG, H1 2015 59

Epithelial Ovarian Cancer-Pipeline by Oasmia Pharmaceutical AB, H1 2015 60

Epithelial Ovarian Cancer-Pipeline by OBI Pharma, Inc., H1 2015 61

Epithelial Ovarian Cancer-Pipeline by Oncobiologics, Inc., H1 2015 62

Epithelial Ovarian Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 63

Epithelial Ovarian Cancer-Pipeline by Onxeo SA, H1 2015 64

Epithelial Ovarian Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 65

Epithelial Ovarian Cancer-Pipeline by Oxford BioMedica plc, H1 2015 66

Epithelial Ovarian Cancer-Pipeline by OXiGENE, Inc., H1 2015 67

Epithelial Ovarian Cancer-Pipeline by Pfizer Inc., H1 2015 68

Epithelial Ovarian Cancer-Pipeline by Pharma Mar, S.A., H1 2015 69

Epithelial Ovarian Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 70

Epithelial Ovarian Cancer-Pipeline by Prima BioMed Ltd., H1 2015 71

Epithelial Ovarian Cancer-Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 72

Epithelial Ovarian Cancer-Pipeline by Sanofi, H1 2015 73

Epithelial Ovarian Cancer-Pipeline by Sanofi Pasteur SA, H1 2015 74

Epithelial Ovarian Cancer-Pipeline by Sotio a.s., H1 2015 75

Epithelial Ovarian Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 76

Epithelial Ovarian Cancer-Pipeline by Tesaro, Inc., H1 2015 77

Epithelial Ovarian Cancer-Pipeline by TetraLogic Pharmaceuticals, H1 2015 78

Epithelial Ovarian Cancer-Pipeline by Therapeutic Proteins International, LLC, H1 2015 79

Epithelial Ovarian Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 80

Epithelial Ovarian Cancer-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 81

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Stage and Target, H1 2015 84

Number of Products by Stage and Mechanism of Action, H1 2015 88

Number of Products by Stage and Route of Administration, H1 2015 91

Number of Products by Stage and Molecule Type, H1 2015 93

Epithelial Ovarian Cancer Therapeutics-Recent Pipeline Updates, H1 2015 244

Epithelial Ovarian Cancer-Dormant Projects, H1 2015 373

Epithelial Ovarian Cancer-Dormant Projects (Contd..1), H1 2015 374

Epithelial Ovarian Cancer-Discontinued Products, H1 2015 375

List of Figures

Number of Products under Development for Epithelial Ovarian Cancer, H1 2015 16

Number of Products under Development for Epithelial Ovarian Cancer-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 82

Number of Products by Top 10 Targets, H1 2015 83

Number of Products by Stage and Top 10 Targets, H1 2015 83

Number of Products by Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 87

Number of Products by Top 10 Routes of Administration, H1 2015 90

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 91

Number of Products by Top 10 Molecule Types, H1 2015 92

Number of Products by Stage and Top 10 Molecule Types, H1 2015 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Adaptimmune Limited

Amgen Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

Bayer AG

Bionomics Limited

BioNumerik Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

Celon Pharma Sp. z o.o.

Celsion Corporation

Cerulean Pharma, Inc.

Clovis Oncology, Inc.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Glycotope GmbH

ImmunoGen, Inc.

Immunotope, Inc.

Johnson & Johnson

MabVax Therapeutics Holdings, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

NeoStem, Inc.

Novartis AG

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Oncobiologics, Inc.

Oncolytics Biotech Inc.

Onxeo SA

Otsuka Holdings Co., Ltd.

Oxford BioMedica plc

OXiGENE, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Prima BioMed Ltd.

PsiOxus Therapeutics, Ltd.

Sanofi

Sanofi Pasteur SA

Sotio a.s.

Synta Pharmaceuticals Corp.

Tesaro, Inc.

TetraLogic Pharmaceuticals

Therapeutic Proteins International, LLC

TRACON Pharmaceuticals, Inc.

VentiRx Pharmaceuticals, Inc.

Epithelial Ovarian Cancer Therapeutic Products under Development, Key Players in Epithelial Ovarian Cancer Therapeutics, Epithelial Ovarian Cancer Pipeline Overview, Epithelial Ovarian Cancer Pipeline, Epithelial Ovarian Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com